BiotechTube
Home/Lantheus Holdings/Mary Anne Heino
MA

Mary Anne Heino

President and Chief Executive Officer, Director

Lantheus Holdings

Therapeutic Areas

OncologyCardiology

Lantheus Holdings Pipeline

DrugIndicationPhase
PYLARIFY (piflufolastat F 18)Prostate Cancer (Diagnostic Imaging)Approved/Commercial
PYLARIFY AIAnalysis of PYLARIFY PET imagesApproved/Commercial
DefinityCardiac Ultrasound ImagingApproved/Commercial
PNT2002Metastatic Castration-Resistant Prostate Cancer (mCRPC)Phase 3
Pnt2003Prostate Cancer (Therapeutic)Phase 1
LNTH-101Solid Tumor Imaging (Pan-Cancer)Phase 1
18F-FlurpiridazMyocardial Perfusion ImagingPhase 3
LMI 1195Cardiac Neurotransmission ImagingPreclinical/Phase 1

Leadership Team at Lantheus Holdings

BM
Brian Markison
Chairman of the Board
PB
Paul Blanchfield
Chief Financial Officer
EM
Etienne Montagut
Chief Business Officer
LT
Lizzy Tsu
Chief Legal Officer and Corporate Secretary
VG
Vipin Garg
Chief Technology Officer
CL
Caroline Loew
Chief Scientific Officer
MK
Mark K. Tsuchiyama
Chief Accounting Officer and Corporate Controller
KA
Karen A. Ling
Chief Corporate Affairs Officer
DM
Daniel M. Niedzwiecki
Chief Medical Officer
CN
Claude Nicaise
Executive Vice President, Research & Development and Medical Affairs
View full Lantheus Holdings profile